Pioneering mRNA Therapies to Combat Hypercholesterolemia and Improve Long-Term Health Repair Biotechnologies, a preclinical biotech, is developing innovative therapies for age-related diseases such as hypercholesterolemia. Their lead asset aims to address the underlying cause of atherosclerosis, representing their ambition to…
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and…
COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its…
In the fast-paced world of early-stage mRNA product and process development, it’s not just about ideas and innovation; it’s about how quickly and accurately you can measure your outcomes. Since those precious outcomes depend on the confidence you have in…
In the latest episode of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The COVID pandemic has brought mRNA into the spotlight, showcasing…
Podcast Abstract: In the latest episode of the Absolute Gene-ius Podcast, hosts Christina Bouwens and Dr. Christian Cobaugh, CEO of Vernal Biosciences, dive into the evolving landscape of mRNA technology and democratizing mRNA technology. With a mission to enhance access…
Poster Abstract: Based on the clinical and commercial success of SARS-CoV-2 mRNA vaccines, interest in using lipid nanoparticle-formulated mRNA (LNP-mRNA) as a next generation, rapidly deployable vaccine platform has accelerated in the form of preclinical research and clinical trials. To…